Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01709032 · ClinicalTrials.gov registry record · Phase 1
Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
A Phase 1 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01709032: Completed Phase 1 study, sponsored by Children's Hospital of Philadelphia.
NCT01709032 is a Phase 1 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01709032, a Phase 1 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.
Primary Outcome
Determine the safety of the combination of Deferasirox and Deferiprone for the treatment of subjects with Thalassemia Major and Severe Iron Overload by assessing change in liver iron concentration from baseline to follow-up
Interventions
- DRUG Deferasirox and deferiprone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-08-01 |
| Phase | Phase 1 |
What the finished NCT01709032 record still lists
NCT01709032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Deferasirox and deferiprone is the first listed.
NCT01709032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01709032 about?
NCT01709032 is a clinical study titled "Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia". We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.
What is the current status of trial NCT01709032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-09. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT01709032?
The interventions under investigation include: Deferasirox and deferiprone (DRUG).
Who is sponsoring clinical trial NCT01709032?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01709032's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia